Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
For women undergoing HPV-based cervical cancer screening, automated evaluation of p16/Ki-67 dual-stained slides reduces the number of colposcopies compared with current standards.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
In addition to high antibody levels, factors including exposure to the human papillomavirus (HPV) and antibody avidity may be important and necessary to protect against infection.
Despite reassuring safety data from clinical trials, the adoption of the inactivated HPV vaccine in the United States remains low.
Survey results reveal HPV vaccine delivery practices and experiences among pediatricians and family physicians.
Studies based on searching Vaccine Adverse Event Reporting System, 6 Vaccine Safety Datalink sites.
Human papillomavirus DNA is detected in the oral cavities of about 6.2% of sexually active female adolescents,
In 2018, adolescent vaccination coverage in the United States continued to improve for meningococcal and HPV vaccines and remains high for tetanus and reduced diphtheria toxoids and acellular pertussis vaccine.
For adults aged 27 to 45 years, vaccination may be beneficial for some who are inadequately vaccinated.
Educational videos produced the highest rate of acceptability and knowledge.
Prevalence of HPV 16 and 18 decreased; anogenital wart diagnoses down in girls, women, boys, men.
Most lifetime QALYs seen with cytologic testing every 3 years, repeated for ASC-US.
Antibody titers to the HPV4 vaccine were lower for all HPV serotypes in individuals who were infected with HIV perinatally than those who were exposed to HIV perinatally.
Compared with liquid-based cytology, routine primary hrHPV screening better detected cervical intraepithelial neoplasia grade 3 or worse and cervical cancer.
Parents of racial or ethnic minority adolescents were more likely to inaccurately report HPV vaccination initiation.
Only 15.7 and 34.8% of teens completed HPV vaccination before turning 13 and 15.